# Article information:

抗PD-1/PD-L1免疫疗法在癌症中的作用  
<https://www.onclive.com/view/role-of-anti-pd-1-pd-l1-immunotherapy-in-cancer>

# Article summary:

1. Immunotherapy has become an increasingly attractive treatment strategy for cancer patients, with many late-stage clinical trials demonstrating overall survival (OS) advantages for melanoma and castration-resistant prostate cancer.

2. This supplement reviews the clinical principles of targeting the PD-1/PD-L1 pathway, including a comprehensive review of ongoing clinical trials assessing the potential of targeted immunotherapy in cancer drug development.

3. Emerging clinical data suggests that targeted immunotherapy will become a part of the clinical management strategy for solid tumors.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article provides an overview of the use of PD-1/PD-L1 immunotherapy in cancer treatment, discussing its potential benefits and current research into its efficacy. The article is well written and provides a comprehensive overview of the topic, covering both passive and active immunotherapies as well as discussing some existing treatments such as Rituxan and Herceptin.

The article is generally reliable and trustworthy, providing evidence to support its claims where appropriate. It also discusses potential risks associated with immunotherapies, noting that they can be ineffective or even cause harm in some cases. However, there are some areas where the article could be improved upon. For example, it does not discuss any potential ethical issues associated with using immunotherapies in cancer treatment or explore any counterarguments to its claims about their efficacy. Additionally, it does not provide any information on cost or availability of these treatments which could be important considerations for patients considering them as an option.

In conclusion, this article provides a comprehensive overview of PD-1/PD-L1 immunotherapies in cancer treatment and is generally reliable and trustworthy in its presentation of information. However, it could be improved by exploring potential ethical issues associated with these treatments as well as providing more information on cost and availability to give readers a more complete picture of their use in practice.

# Topics for further research:

* Ethical implications of PD-1/PD-L1 immunotherapy
* Cost of PD-1/PD-L1 immunotherapy
* Availability of PD-1/PD-L1 immunotherapy
* Counterarguments to PD-1/PD-L1 immunotherapy efficacy
* Risks associated with PD-1/PD-L1 immunotherapy
* Comparative effectiveness of PD-1/PD-L1 immunotherapy vs other treatments

# Report location:

<https://www.fullpicture.app/item/7f157652d1e0c2a6ede5041a41eeb93d>